The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas Review
| Authors: | Offin, M.; Fitzgerald, B.; Zauderer, M. G.; Doroshow, D. |
| Review Title: | The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas |
| Abstract: | Despite our growing understanding of the genomic landscape of diffuse pleural mesotheliomas (DPM), there has been limited success in targeted therapeutic strategies for the disease. This review summarizes attempts to develop targeted therapies in DPM, focusing on the following targets being clinically explored in recent and ongoing clinical trials: vascular endothelial growth factor, mesothelin, BRCA1-associated protein 1, Wilms tumor 1 protein, NF2/YAP/TAZ, CDKN2, methylthioadenosine phosphorylase, v-domain Ig suppressor T-cell activation, and argininosuccinate synthetase 1. Although preclinical data for these targets are promising, few have efficaciously translated to benefit our patients. Future efforts should seek to expand the availability of preclinical models that faithfully recapitulate DPM biology, develop clinically relevant biomarkers, and refine patient selection criteria for clinical trials. © The Author(s) 2023. |
| Keywords: | biomarkers; mesothelioma; genomics; targeted therapy |
| Journal Title: | Journal of Cancer Metastasis and Treatment |
| Volume: | 9 |
| ISSN: | 2394-4722 |
| Publisher: | OAE Publishing Inc. |
| Date Published: | 2023-05-31 |
| Start Page: | 21 |
| Language: | English |
| DOI: | 10.20517/2394-4722.2022.140 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding author is Michael Offin -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work